No Prescription |
 |
 | ||
|
Cardace |
|
| ||
No Prescription » Prescription Drugs 3 » Cardace This drug belongs to a group of medications called ACE inhibitors. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels causing them to widen. Lowering high blood pressure helps prevent strokes heart attacks and kidney problems.This medication is also used to prevent heart problems (such as heart attacks) and/or strokes in certain high risk patients and with other drugs (e.g. "water pills"/diuretics digoxin) to treat congestive heart failure. Buy Cardace and other Prescription Drugs 3 products online at Medstore. Buy Online at Medstore - Click Here!
About Cardace: Product Type: Prescription Drugs 3 Cardace/Altace (Generic Ramipril ) Cardace/Altace (Generic Ramipril) Generic Ramipril 1.25mg 150 Tablets 1.25mg 300(2 x 150 Tablets) 1.25mg 600(4 x 150 tablets) 10mg 100 Tablets 10mg 200(2 x 100 Tablets) 10mg 400(4 x 100 Tablets) 2.5mg 150 Tablets 2.5mg 300(2 x 150 Tablets) 2.5mg 600(4 x 150 Tablets) 5mg 150 Tablets 5mg 300(2 x 150 Tablets) 5mg 600(4 x 150 Tablets) Generic Ramipril Cardace/Altace
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
